Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib vs bortezomib in transplant-ineligible newly diagnosed multiple myeloma (China)
CTR20140135Phase 3Active
- Sponsor
- Onyx Pharmaceuticals
- Start
- May 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by Onyx Pharmaceuticals. Started May 2014; status: active.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20140135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140135.